How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about osimertinib with pemetrexed and platinum-based chemotherapy

Marketing authorisation indication

2.1

Osimertinib with pemetrexed and platinum-based chemotherapy (Tagrisso, AstraZeneca) is indicated for 'the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations'.

Dosage in the marketing authorisation

2.2

The dosage schedule is available in the summary of product characteristics for osimertinib.

Price

2.3

The list price of osimertinib is £5,770 per pack of 30 tablets in either 40‑mg or 80‑mg doses (excluding VAT; BNF online accessed October 2024).

2.4

The list price of pemetrexed (25 mg/ml) varies between £128 and £160 per 4‑ml vial, between £640 and £800 per 20‑ml vial, between £1,280 and £1,600 per 40‑ml vial, and is £1,360 per 34‑ml vial (excluding VAT; BNF online accessed October 2024).

2.5

The company has a commercial arrangement. This makes osimertinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence.